Structure-based Vaccine Design for CCHFV

基于结构的 CCHFV 疫苗设计

基本信息

批准号：
10405068
负责人：
Kartik Chandran
金额：
$ 42.85万
依托单位：
UNIVERSITY OF TEXAS AT AUSTIN
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-06-25 至 2025-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10405068
关键词：
Acute Africa Animal Model Antibodies Antibody Response Antibody Therapy Antigens Case Fatality Rates Categories Category A pathogen Cells Central Asia Chimeric Proteins Complex Coronavirus Crimean Hemorrhagic Fever Crimean-Congo Hemorrhagic Fever Virus Crystallization Data Data Protection Disease Disease Outbreaks Dyes Engineering Epitope Mapping Epitopes Evaluation Family Filovirus Funding Genome Geographic Locations Glycoproteins Goals Human IFNAR1 gene Immune response Immunocompromised Host Immunologics Incidence International Laboratories Laboratory Animal Models Life Livestock Maps Membrane Fusion Middle East Molecular Monoclonal Antibodies Morbidity - disease rate Mucins Mus Nairovirus National Institute of Allergy and Infectious Disease Pathogenesis Patients Process Proteins Public Health RNA Viruses Reagent Respiratory syncytial virus Sampling Site Southern Europe Structure Subunit Vaccines Technology Therapeutic antibodies Tick-Borne Diseases Ticks Vaccine Antigen Vaccine Design Vaccines Viral Viral Envelope Proteins Viral Genome Viral Hemorrhagic Fevers Virus Virus Diseases Western Asia Work base clinical development cross reactivity design disorder prevention experience global temperature immunogenicity in vivo insight interest lead candidate medical countermeasure migratory bird mortality mouse model nanoparticle neutralizing antibody novel novel vaccines prevent structural glycoprotein tick-borne tick-borne pathogen tool type I interferon receptor vaccine candidate vaccine development vector

项目摘要

Project Summary/Abstract Crimean-Congo hemorrhagic fever virus (CCHFV) causes a life-threatening tick-borne disease in humans. The disease presents as a severe form of hemorrhagic fever with a case fatality rate of 10–40%. CCHFV outbreaks have spanned a wide geographic area ranging from Western and Central Asia, the Middle East, Africa and Southern Europe. Increasing global temperatures, migratory birds, and the international livestock trade have all potentially contributed toward the spread of Hyalomma ticks—the primary vector for CCHFV. Expanding endemic zones, widespread morbidity and significant mortality make CCHFV an acute threat to public health and thus is listed as a NIAID Category A priority pathogen. The viral genome encodes a glycoprotein precursor that is processed into two structural glycoproteins—Gn and Gc—and two secreted glycoproteins—a mucin-like domain and GP38. Protective antibodies have been isolated that target Gc or GP38, suggesting that these two proteins should be given priority for vaccine development. Here we propose to engineer Gc- and GP38-based immunogens that focus the immune response onto broadly conserved epitopes that are capable of eliciting protective antibody responses. To accomplish our goal, we will structurally characterize CCHFV glycoproteins and their interactions with human-derived antibodies, rationally engineer vaccine antigens based in part on the structural information, and characterize the immune responses elicited by these antigens in animal models. These results will be used to guide further improvements of the immunogens, including display on self-assembling multi-valent nanoparticles, and the most promising candidates will be evaluated in a lethal murine model of CCHFV challenge. Given our expertise, unique reagents, and preliminary data, we are confident that we can deliver a state-of-the-art subunit vaccine candidate with the potential to induce cross-reactive protective antibodies, thereby satisfying an unmet need against this NIAID Category A tick-borne pathogen.

项目概要/摘要克里米亚-刚果出血热病毒（CCHFV）会导致人类致命的蜱传疾病。该病表现为一种严重的出血热，病死率为 10-40%。疫情蔓延范围广泛，包括西亚、中亚、中东、非洲和南欧全球气温升高、候鸟和国际牲畜。贸易都可能导致透明蜱蜱（CCHFV 的主要传播媒介）的传播。流行区的扩大、广泛的发病率和高死亡率使 CCHFV 成为严重威胁公共卫生，因此被列为 NIAID A 类优先病原体。该病毒基因组编码一种病毒。糖蛋白前体，被加工成两种结构糖蛋白——Gn和Gc——以及两种分泌型糖蛋白糖蛋白——一种粘蛋白样结构域和 GP38 已被分离出来，以 Gc 或 GP38，表明这两种蛋白应该优先用于疫苗开发。建议设计基于 Gc 和 GP38 的免疫原，将免疫反应集中于广泛的能够引发保护性抗体反应的保守表位为了实现我们的目标，我们将在结构上表征 CCHFV 糖蛋白及其与人源抗体的相互作用，部分基于结构信息合理设计疫苗抗原，并表征这些结果将用于指导动物模型中这些抗原进一步引发的免疫反应。免疫原的改进，包括在自组装多价纳米粒子上的展示，以及鉴于我们的研究，最有前途的候选者将在 CCHFV 挑战的致命小鼠模型中进行评估。专业知识、独特的试剂和初步数据，我们有信心能够提供最先进的候选亚单位疫苗具有诱导交叉反应性保护性抗体的潜力，从而满足针对 NIAID A 类蜱传病原体的未满足需求。